TG THERAPEUTICS INC. - COMMON STOCK

28,77

08-января-25 15:45:00

15 мин. задержка

Акции

+0,77

+2,75%

Сегодняшний диапазон

27,55 - 28,88

ISIN

N/A

Источник

NASDAQ

TG Therapeutics Announces Data from the UNITY-CLL Phase 3 Trial Presented at the 63rd American Society of Hematology (ASH) Annual Meeting

14 дек 2021 06:30:00 Источник Nasdaq GlobeNewswire
TG Therapeutics Announces FDA Acceptance of Biologics License Application for Ublituximab as a Treatment for Patients with Relapsing Forms of Multiple Sclerosis

14 дек 2021 06:15:00 Источник Nasdaq GlobeNewswire
TG Therapeutics Announces Data Presentations at the 63rd American Society of Hematology (ASH) Annual Meeting

13 дек 2021 06:30:00 Источник Nasdaq GlobeNewswire
TG Therapeutics Recaps Schedule of Data Presentations at the Upcoming 63rd American Society of Hematology (ASH) Annual Meeting

10 дек 2021 06:30:00 Источник Nasdaq GlobeNewswire
TG Therapeutics Provides Regulatory Update

30 ноя 2021 06:30:00 Источник Nasdaq GlobeNewswire
TG Therapeutics to Participate in the Jefferies London Healthcare Conference

15 ноя 2021 06:30:01 Источник Nasdaq GlobeNewswire
TG Therapeutics Highlights Data Selected for Presentation at the 63rd American Society of Hematology (ASH) Annual Meeting

04 ноя 2021 08:34:14 Источник Nasdaq GlobeNewswire
TG Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results

04 ноя 2021 06:00:02 Источник Nasdaq GlobeNewswire
TG Therapeutics to Host Conference Call on Third Quarter 2021 Financial Results and Business Update

01 ноя 2021 06:30:00 Источник Nasdaq GlobeNewswire
TG Therapeutics Announces Data for Ublituximab in Multiple Sclerosis Presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis

14 окт 2021 09:45:00 Источник Nasdaq GlobeNewswire
TG Therapeutics Submits Biologics License Application to the U.S. Food and Drug Administration for Ublituximab as a Treatment for Patients with Relapsing Forms of Multiple Sclerosis

30 сен 2021 06:30:00 Источник Nasdaq GlobeNewswire
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis

29 сен 2021 06:30:00 Источник Nasdaq GlobeNewswire
TG Therapeutics Announces Publication of Results from an Integrated Safety Analysis of UKONIQ® (umbralisib) in Blood Advances

23 сен 2021 07:00:01 Источник Nasdaq GlobeNewswire
TG Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference

23 сен 2021 06:30:00 Источник Nasdaq GlobeNewswire
TG Therapeutics Announces Combination Data Presentations at the XIX International Workshop on Chronic Lymphocytic Leukemia (iwCLL)

20 сен 2021 06:30:00 Источник Nasdaq GlobeNewswire
TG Therapeutics Recaps Schedule of Upcoming Data Presentations at the XIX International Workshop on Chronic Lymphocytic Leukemia (iwCLL)

13 сен 2021 08:21:06 Источник Nasdaq GlobeNewswire
TG Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

09 сен 2021 08:00:01 Источник Nasdaq GlobeNewswire
TG Therapeutics Announces Data Presentations at the Upcoming XIX International Workshop on Chronic Lymphocytic Leukemia (iwCLL)

30 авг 2021 06:30:00 Источник Nasdaq GlobeNewswire
TG Therapeutics Provides Business Update and Reports Second Quarter 2021 Financial Results

02 авг 2021 06:00:00 Источник Nasdaq GlobeNewswire
TG Therapeutics to Host Conference Call on Second Quarter 2021 Financial Results and Business Update

28 июл 2021 06:30:00 Источник Nasdaq GlobeNewswire

<<
<
2
3
4
5
6
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.